The effect of surface demineralization of cortical bone allograft on the properties of recombinant adeno-associated virus coatings

Biomaterials

Volumn 29, Issue 28, 2008, Pages 3882-3887

  Yazici, Cemal ^a   Yanoso, Laura ^a,b   Xie, Chao ^a   Reynolds, David G ^a,b   Samulski, R Jude ^c,d   Samulski, Jade ^d   Yannariello Brown, Judith ^e   Gertzman, Arthur A ^e   Zhang, Xinping ^a   Awad, Hani A ^a,b   Schwarz, Edward M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b University of Rochester   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d ASKLEPIOS BIOPHARMACEUTICAL INC   (United States)

^e Musculoskeletal Transplant Foundation   (United States)

Author keywords

Allograft; Bioluminescence imaging (BLI); Bone; Freeze dried; Recombinant adeno associated virus (rAAV)

Indexed keywords

(1 1 0) SURFACE; (PL) PROPERTIES; ABSORBANCE; ADENO-ASSOCIATED VIRUS (AAV); CORTICAL BONES; CORTICAL SURFACES; DOSE RESPONSES; IN-VIVO; OSTEOINTEGRATION; REVASCULARIZATION; TRANSDUCTION EFFICIENCY; UNIFOR M DISTRIBUTION;

FIREFLY LUCIFERASE;

ABSORPTION; ARTICLE; BIOLUMINESCENCE; BONE ALLOGRAFT; BONE DEMINERALIZATION; CORTICAL BONE; DOSE RESPONSE; FREEZE DRYING; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN TISSUE; KINETICS; PRIORITY JOURNAL; RECOMBINANT ADENO ASSOCIATED VIRUS; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY;

ANIMALS; BONE AND BONES; CALCIFICATION, PHYSIOLOGIC; COATED MATERIALS, BIOCOMPATIBLE; DEPENDOVIRUS; HUMANS; MATERIALS TESTING; MICE; SURFACE PROPERTIES; TRANSPLANTATION, HOMOLOGOUS;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 47849125945     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.06.007     Document Type: Article

References (40)

1. Lord C.F., Gebhardt M.C., Tomford W.W., and Mankin H.J. Infection in bone allografts. Incidence, nature, and treatment. J Bone Joint Surg Am 70 (1988) 369-376
2. Berrey Jr. B.H., Lord C.F., Gebhardt M.C., and Mankin H.J. Fractures of allografts. Frequency, treatment, and end-results. J Bone Joint Surg Am 72 (1990) 825-833
3. Enneking W.F., and Campanacci D.A. Retrieved human allografts: a clinicopathological study. J Bone Joint Surg Am 83-A (2001) 971-986
4. Hornicek F.J., Gebhardt M.C., Tomford W.W., Sorger J.I., Zavatta M., Menzner J.P., et al. Factors affecting nonunion of the allograft-host junction. Clin Orthop Relat Res 382 (2001) 87-98
5. Wheeler D.L., and Enneking W.F. Allograft bone decreases in strength in vivo over time. Clin Orthop Relat Res 435 (2005) 36-42
6. Ito H., Koefoed M., Tiyapatanaputi P., Gromov K., Goater J.J., Carmouche J., et al. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med 11 (2005) 291-297
7. Koefoed M., Ito H., Gromov K., Reynolds D.G., Awad H.A., Rubery P.T., et al. Biological effects of rAAV-caAlk2 coating on structural allograft healing. Mol Ther 12 (2005) 212-218
8. Basile P., Dadali T., Jacobson J., Hasslund S., Ulrich-Vinther M., Soballe K., et al. Freeze-dried tendon allografts as tissue-engineering scaffolds for Gdf5 gene delivery. Mol Ther 16 (2008) 466-473
9. Sharif F., Hynes S.O., McMahon J., Cooney R., Conroy S., Dockery P., et al. Gene-eluting stents: comparison of adenoviral and adeno- associated viral gene delivery to the blood vessel wall in vivo. Hum Gene Ther 17 (2006) 741-750
10. Awad H.A., Zhang X., Reynolds D.G., Guldberg R.E., O'Keefe R.J., and Schwarz E.M. Recent advances in gene delivery for structural bone allografts. Tissue Eng 13 (2007) 1973-1985
11. Corsi K.A., Schwarz E.M., Mooney D.J., and Huard J. Regenerative medicine in orthopaedic surgery. J Orthop Res 25 (2007) 1261-1268
12. Patel R., and Trampuz A. Infections transmitted through musculoskeletal-tissue allografts. N Engl J Med 350 (2004) 2544-2546
13. Kwong F.N., Ibrahim T., and Power R.A. Incidence of infection with the use of non-irradiated morcellised allograft bone washed at the time of revision arthroplasty of the hip. J Bone Joint Surg Br 87 (2005) 1524-1526
14. Delloye C., Cornu O., Druez V., and Barbier O. Bone allografts: what they can offer and what they cannot. J Bone Joint Surg Br 89 (2007) 574-579
15. Bondre S., Lewandrowski K.U., Hasirci V., Cattaneo M.V., Gresser J.D., Wise D.L., et al. Biodegradable foam coating of cortical allografts. Tissue Eng 6 (2000) 217-227
16. Lewandrowski K.U., Bondre S., Hile D.D., Thompson B.M., Wise D.L., Tomford W.W., et al. Porous poly(propylene fumarate) foam coating of orthotopic cortical bone grafts for improved osteoconduction. Tissue Eng 8 (2002) 1017-1027
17. Schantz J.T., Hutmacher D.W., Lam C.X., Brinkmann M., Wong K.M., Lim T.C., et al. Repair of calvarial defects with customised tissue-engineered bone grafts II. Evaluation of cellular efficiency and efficacy in vivo. Tissue Eng 9 Suppl. 1 (2003) S127-S139
18. Childs L.M., Goater J.J., O'Keefe R.J., and Schwarz E.M. Efficacy of etanercept for wear debris-induced osteolysis. J Bone Miner Res 16 (2001) 338-347
19. Xiao X., Li J., and Samulski R.J. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72 (1998) 2224-2232
20. Smith J.S., Tian J., Muller J., and Byrnes A.P. Unexpected pulmonary uptake of adenovirus vectors in animals with chronic liver disease. Gene Ther 11 (2004) 431-438
21. Thierry A.R., Lunardi-Iskandar Y., Bryant J.L., Rabinovich P., Gallo R.C., and Mahan L.C. Systemic gene therapy: biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci U S A 92 (1995) 9742-9746
22. Moutsatsos I.K., Turgeman G., Zhou S., Kurkalli B.G., Pelled G., Tzur L., et al. Exogenously regulated stem cell-mediated gene therapy for bone regeneration. Mol Ther 3 (2001) 449-461
23. Xie C., Reynolds D., Awad H., Rubery P.T., Pelled G., Gazit D., et al. Structural bone allograft combined with genetically engineered mesenchymal stem cells as a novel platform for bone tissue engineering. Tissue Eng 13 (2007) 435-445
24. Bragdon C.R., Doherty A.M., Rubash H.E., Jasty M., Li X.J., Seeherman H., et al. The efficacy of BMP-2 to induce bone ingrowth in a total hip replacement model. Clin Orthop Relat Res (2003) 50-61
25. Jones A.L., Bucholz R.W., Bosse M.J., Mirza S.K., Lyon T.R., Webb L.X., et al. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 88 (2006) 1431-1441
26. Boden S.D., Zdeblick T.A., Sandhu H.S., and Heim S.E. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine 25 (2000) 376-381
27. Burkus J.K., Sandhu H.S., Gornet M.F., and Longley M.C. Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am 87 (2005) 1205-1212
28. Pelled G., G T Aslan H., Gazit Z., and Gazit D. Mesenchymal stem cells for bone gene therapy and tissue engineering. Curr Pharm Des 8 (2002) 1917-1928
29. Dragoo J.L., Choi J.Y., Lieberman J.R., Huang J., Zuk P.A., Zhang J., et al. Bone induction by BMP-2 transduced stem cells derived from human fat. J Orthop Res 21 (2003) 622-629
30. Arinzeh T.L., Peter S.J., Archambault M.P., van den Bos C., Gordon S., Kraus K., et al. Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am 85-A (2003) 1927-1935
31. Usas A., and Huard J. Muscle-derived stem cells for tissue engineering and regenerative therapy. Biomaterials 28 (2007) 5401-5406
32. Lieberman J.R., Daluiski A., Stevenson S., Wu L., McAllister P., Lee Y.P., et al. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg Am 81 (1999) 905-917
33. Bonadio J., Smiley E., Patil P., and Goldstein S. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration. Nat Med 5 (1999) 753-759
34. Peng H., Wright V., Usas A., Gearhart B., Shen H.C., Cummins J., et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110 (2002) 751-759
35. Southwood L.L., Frisbie D.D., Kawcak C.E., Ghivizzani S.C., Evans C.H., and McIlwraith C.W. Evaluation of Ad-BMP-2 for enhancing fracture healing in an infected defect fracture rabbit model. J Orthop Res 22 (2004) 66-72
36. Gafni Y., Pelled G., Zilberman Y., Turgeman G., Apparailly F., Yotvat H., et al. Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol Ther 9 (2004) 587-595
37. Evans C.H., Ghivizzani S.C., Herndon J.H., and Robbins P.D. Gene therapy for the treatment of musculoskeletal diseases. J Am Acad Orthop Surg 13 (2005) 230-242
38. Nixon A.J., Goodrich L.R., Scimeca M.S., Witte T.H., Schnabel L.V., Watts A.E., et al. Gene therapy in musculoskeletal repair. Ann N Y Acad Sci 1117 (2007) 310-327
39. Feeley B.T., Conduah A.H., Sugiyama O., Krenek L., Chen I.S., and Lieberman J.R. In vivo molecular imaging of adenoviral versus lentiviral gene therapy in two bone formation models. J Orthop Res 24 (2006) 1709-1721
40. Einhorn T.A. The cell and molecular biology of fracture healing. Clin Orthop (1998) S7-S21